Download PDF
J Pediatr Infect Dis 2022; 17(02): 106-111
DOI: 10.1055/s-0042-1743576
Original Article

Is Serum Endocan Level an Indicator of the Severity of Childhood Community-Acquired Pneumonia?

Hayrunnisa Bekis Bozkurt 
1   Department of Pediatrics, Faculty of Medicine, Kafkas University, Kars, Turkey
,
Abdullah Gümüs 
2   Department of Microbiology, Faculty of Medicine, Kafkas University, Kars, Turkey
,
Müferet Ergüven 
1   Department of Pediatrics, Faculty of Medicine, Kafkas University, Kars, Turkey
› Author Affiliations Funding This article received its financial support from Kafkas University Scientific Research Projects Commission (Project no: 2019-TS-22).
› Further Information
    Permissions and Reprints

Abstract

Objective We aimed to investigate the relationship between serum endocan, procalcitonin (PCT), C-reactive protein (CRP), white blood cell count (WBC), neutrophil/lymphocyte ratios (NLR), and the severity of the disease in childhood community-acquired pneumonia (CAP) cases.

Methods This cross-sectional designed study included 30 pneumonia cases and 30 severe pneumonia cases aged between 3 months and 18 years who were hospitalized and treated in our hospital with the diagnosis of CAP. We also included 30 healthy controls in the same age range. Pearson's correlation and receiver operating characteristic (ROC) curve analyzes were performed.

Results PCT, endocan, NLR, and CRP levels were found to be significantly higher in patients with severe pneumonia. Sensitivity and specificity values in detecting pneumonia were 72.5 and 93% for PCT, 78.4 and 83.3% for CRP, 78.4 and 76.7% for endocan, and 64.7 and 63.3% for NLR. However, the area under the curve in ROC analysis were 0.821, 0.840, 0.842, and 0.670 for PCT, CRP, endocan, and NLR respectively.

Conclusion Endocan may be a marker of the diagnosis of pneumonia and not clinical severity, but studies are needed in large patient populations.

Keywords

endocan - procalcitonin - pneumonia - children


Publication History

Received: 04 August 2021

Accepted: 01 February 2022

Article published online:
07 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 le Roux DM, Zar HJ. Community-acquired pneumonia in children - a changing spectrum of disease. Pediatr Radiol 2017; 47 (11) 1392-1398
    CrossrefPubMedGoogle Scholar
  • 2 Rudan I, O'Brien KL, Nair H. et al; Child Health Epidemiology Reference Group (CHERG). Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health 2013; 3 (01) 010401
    PubMedGoogle Scholar
  • 3 Bradley JS, Byington CL, Shah SS. et al; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53 (07) e25-e76
    CrossrefPubMedGoogle Scholar
  • 4 Zhang TG, Li AH, Lyu M, Chen M, Huang F, Wu J. Detection of respiratory viral and bacterial pathogens causing pediatric community-acquired pneumonia in Beijing using real-time PCR. Chronic Dis Transl Med 2015; 1 (02) 110-116
    PubMedGoogle Scholar
  • 5 Zheng N, Zhu D, Han Y. Procalcitonin and C-reactive protein perform better than the neutrophil/lymphocyte count ratio in evaluating hospital acquired pneumonia. BMC Pulm Med 2020; 20 (01) 166
    CrossrefPubMedGoogle Scholar
  • 6 Gillette MA, Mani DR, Uschnig C. et al. Biomarkers to distinguish bacterial from viral pediatric clinical pneumonia in a malaria endemic setting. Clin Infect Dis 2021; 73 (11) e3939-e3948
    CrossrefPubMedGoogle Scholar
  • 7 Bekis Bozkurt H. Is there any relationship between C-reactive protein/albumin ratio and clinical severity of childhood community-acquired pneumonia. Turkish J Biochem 2021; 46 (06) 647-653
    CrossrefPubMedGoogle Scholar
  • 8 Lassalle P, Molet S, Janin A. et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996; 271 (34) 20458-20464
    CrossrefPubMedGoogle Scholar
  • 9 Gaudet A, Parmentier E, Dubucquoi S. et al. Low endocan levels are predictive of acute respiratory distress syndrome in severe sepsis and septic shock. J Crit Care 2018; 47: 121-126
    CrossrefPubMedGoogle Scholar
  • 10 Kamat IS, Ramachandran V, Eswaran H, Abers MS, Musher DM. Low procalcitonin, community acquired pneumonia, and antibiotic therapy. Lancet Infect Dis 2018; 18 (05) 496-497
    CrossrefPubMedGoogle Scholar
  • 11 An SJ, Bae SP, Park JS, Choi YJ, Lim HH, Lee JH. Antibiotic therapy decision and clinical outcome comparison based on serum procalcitonin in children with pneumonia. J Allergy. Asthma Respiratory Disease 2016; 4 (01) 55-60
    CrossrefPubMedGoogle Scholar
  • 12 Hangül M, Öztürk D, Keti DB, Köse M. Relationship between serum endocan levels and childhood community-acquired pneumonia. Turk Thorac J 2020; 21 (01) 3-7
    CrossrefPubMedGoogle Scholar
  • 13 Paketci C, Paketci A, Erdede O, Demirkol M, Guzel S. Serum endocan levels in children with community-acquired pneumonia. J Pediatr Allergy, Immunol Pulmonol 2017; 30 (02) 80-85
    CrossrefPubMedGoogle Scholar
  • 14 Messinger AI, Kupfer O, Hurst A, Parker S. Management of pediatric community-acquired bacterial pneumonia. Pediatr Rev 2017; 38 (09) 394-409
    CrossrefPubMedGoogle Scholar
  • 15 Esposito S, Principi N. Impacts of the 13-valent pneumococcal conjugate vaccine in children. J Immunol Res 2015; 2015: 591580
    CrossrefPubMedGoogle Scholar
  • 16 Kechagia M, Papassotiriou I, Gourgoulianis KI. Endocan and the respiratory system: a review. Int J Chron Obstruct Pulmon Dis 2016; 11: 3179-3187
    CrossrefPubMedGoogle Scholar
  • 17 Tang L, Zhao Y, Wang D. et al. Endocan levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Mediators Inflamm 2014; 2014: 625180
    CrossrefPubMedGoogle Scholar
  • 18 Mikkelsen ME, Shah CV, Scherpereel A. et al. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 2012; 27 (05) 522.e11-522.e17
    CrossrefPubMedGoogle Scholar
  • 19 Kupeli I, Salcan S, Kuzucu M, Kuyrukluyıldız U. Can endocan be a new biomarker in ventilator-associated pneumonia?. Kaohsiung J Med Sci 2018; 34 (12) 689-694
    CrossrefPubMedGoogle Scholar
  • 20 Seo K, Kitazawa T, Yoshino Y, Koga I, Ota Y. Characteristics of serum endocan levels in infection. PLoS One 2015; 10 (04) e0123358
    CrossrefPubMedGoogle Scholar
  • 21 Kao SJ, Chuang CY, Tang CH. et al. Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia. Clin Chem Lab Med 2014; 52 (03) 445-451
    CrossrefPubMedGoogle Scholar
  • 22 Sartori LF, Zhu Y, Grijalva CG. et al. Pneumonia severity in children: utility of procalcitonin in risk stratification. Hosp Pediatr 2021; 11 (03) 215-222
    CrossrefPubMedGoogle Scholar
  • 23 Florin TA, Ambroggio L, Brokamp C. et al. Biomarkers and disease severity in children with community-acquired pneumonia. Pediatrics 2020; 145 (06) e20193728
    CrossrefPubMedGoogle Scholar
  • 24 Principi N, Esposito S. Biomarkers in pediatric community-acquired pneumonia. Int J Mol Sci 2017; 18 (02) E447
    CrossrefPubMedGoogle Scholar
  • 25 Khan DA, Rahman A, Khan FA. Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children?. J Clin Lab Anal 2010; 24 (01) 1-5
    CrossrefPubMedGoogle Scholar
  • 26 Neuman MI, Hall M, Lipsett SC. et al; Pediatric Research in Inpatient Settings Network. Utility of blood culture among children hospitalized with community-acquired pneumonia. Pediatrics 2017; 140 (03) e20171013
    CrossrefPubMedGoogle Scholar